So fortuitous that I just PM’d a poster here this morning just prior to the announcement of the term sheet stating that IPIX actions certainly seem, to someone who had been in the industry for a bit, that there was a BP significantly interested. Well, there you go. I enjoy the conjecture on the boards.
Working out B’s effect on the various GI mucosal regions will be interesting and really cannot wait to read the research. From the technical side of things, there are significant differences between oral, small bowel and colonic mucosa and B’s effect on these will be interesting.
Having a daughter with Crohn’s, if B is extended to that, taking a pill which adds what is deficient compared to injection/infusion of antibodies which nonspecifically block the functions of an essential cytokine with all its inherent side effects and immunosuppression, would be an enormous game changer, literally a paradigm shift.
Lastly, my personal philosophy is that it really is great to get some concreteness to this stock, if the deal is signed. That said, the road is still not short but my timeline is such that I will continue to accumulate and wait. With the indications which are being addressed, IBD, OM, MRSA, and cancer (K), this company has the potential to become a juggernaut. And that is with only one of the acrylamide based HDMs. Now, they gave up the rights to another that was tested against resistant Candida. From an Infectious Disease standpoint, fungal infections are extremely common and becoming challenging to treat (eg mdr Candida). For those who are thinking persistent athletes foot, think again. I am talking end organ infection, sepsis and death. This HDM platform will, in my opinion, has the potential to cause widespread changes in the way we approach a patient.
Very long and looking forward to the ride
Working out B’s effect on the various GI mucosal regions will be interesting and really cannot wait to read the research. From the technical side of things, there are significant differences between oral, small bowel and colonic mucosa and B’s effect on these will be interesting.
Having a daughter with Crohn’s, if B is extended to that, taking a pill which adds what is deficient compared to injection/infusion of antibodies which nonspecifically block the functions of an essential cytokine with all its inherent side effects and immunosuppression, would be an enormous game changer, literally a paradigm shift.
Lastly, my personal philosophy is that it really is great to get some concreteness to this stock, if the deal is signed. That said, the road is still not short but my timeline is such that I will continue to accumulate and wait. With the indications which are being addressed, IBD, OM, MRSA, and cancer (K), this company has the potential to become a juggernaut. And that is with only one of the acrylamide based HDMs. Now, they gave up the rights to another that was tested against resistant Candida. From an Infectious Disease standpoint, fungal infections are extremely common and becoming challenging to treat (eg mdr Candida). For those who are thinking persistent athletes foot, think again. I am talking end organ infection, sepsis and death. This HDM platform will, in my opinion, has the potential to cause widespread changes in the way we approach a patient.
Very long and looking forward to the ride
4
